Cogent Biosciences (COGT) Projected to Release Earnings on Friday

Key Points

• Cogent Biosciences is expected to report Q3 2026 results before the market opens on November 6. Analysts forecast a loss of $0.5573 per share and revenue of approximately $0.75 million.
• The company last reported a quarterly loss of $0.52 per share, beating expectations of a $0.55 loss. Analysts project full-year and next-year losses of $2.23 and $1.27 per share, respectively.
• COGT shares opened at $31.96, down 0.8%, while analyst sentiment remains a Moderate Buy with a consensus price target of $51.56; Cogent’s lead drug candidate is bezuclastinib, being developed for systemic mastocytosis.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) is anticipated to announce its Q3 2026 results before the market opens on Friday, November 6th. Analysts expect the company to post earnings of ($0.5573) per share and revenue of $0.75 million for the quarter. Parties can find conference call details on the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Monday, November 2, 2026 at 12:30 PM ET.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) last posted its earnings results on Monday, August 10th. The technology company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.03. On average, analysts expect Cogent Biosciences to post ($2.23) EPS for the current fiscal year and ($1.27) EPS for the next fiscal year.

Cogent Biosciences Stock Down 0.8%

Cogent Biosciences stock opened at $31.96 on Friday. Cogent Biosciences has a one year low of $13.78 and a one year high of $43.73. The stock has a fifty day moving average of $32.51 and a 200 day moving average of $35.72. The company has a debt-to-equity ratio of 0.48, a quick ratio of 13.57 and a current ratio of 13.57. The stock has a market cap of $5.55 billion, a PE ratio of -14.80 and a beta of 0.31.

Analyst Ratings Changes

Several brokerages have recently weighed in on COGT. Weiss Ratings reiterated a "sell (d-)" rating on shares of Cogent Biosciences in a research note on Friday, October 2nd. Guggenheim boosted their target price on shares of Cogent Biosciences from $45.00 to $52.00 and gave the company a "buy" rating in a research report on Wednesday, August 12th. HC Wainwright reaffirmed a "buy" rating and set a $55.00 target price on shares of Cogent Biosciences in a report on Tuesday, September 15th. Wall Street Zen downgraded shares of Cogent Biosciences from a "hold" rating to a "sell" rating in a research report on Saturday, September 5th. Finally, Piper Sandler increased their price target on shares of Cogent Biosciences from $52.00 to $55.00 and gave the stock an "overweight" rating in a research report on Monday, August 17th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $51.56.

About Cogent Biosciences

Cogent Biosciences, Inc is a clinical-stage biotechnology company focused on developing precision medicines for genetically defined diseases. The company uses molecular biology and drug-discovery technologies to design therapies intended to target disease-driving mutations while limiting activity in healthy tissues.

Cogent's lead product candidate is bezuclastinib, also known as CGT9486, an investigational, highly selective inhibitor of the KIT D816V mutation. The company is developing bezuclastinib for systemic mastocytosis, a rare disorder involving the abnormal accumulation of mast cells, including both indolent and advanced forms of the disease.

Cogent conducts its research and clinical-development activities primarily in the United States and works with clinical centers and research partners in support of its development programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.